MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "1-Methyl-4-phenylpyridinium (MPP+)"

  • 2023 International Congress

    Thymoquinone and Edible Bird Nest: The Secret Ingredients to Protect Against MPTP-induced zebrafish Parkinson’s disease

    W. Mohamed (Kuantan, Malaysia)

    Objective: Objectives: to create and validate an MPTP neurotoxin-based zebrafish model of Parkinson's disease and explore the therapeutic potential and neuroprotective effects of thymoquinone and…
  • 2023 International Congress

    Selenium mitigates ferroptosis-mediated dopaminergic cell death by regulating the Nrf2/GPX4 pathway: Implication for Parkinson’s disease

    YJ. Jung, H. Choi, E. Oh (Daejeon, Republic of Korea)

    Objective: The objective of this study is to explore the protective properties of selenium in an in vitro PD model, especially focusing on its underlying…
  • 2023 International Congress

    The effect of anti- Parkinson’s disease granules and probiotics on gastrointestinal motility in the mouse model of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine -induced Parkinson’s disease

    X. Zhao, J. Yang (Shanghai, China)

    Objective: To investigate the effect of anti- Parkinson’s disease (anti-PD granules) and probiotics on gastrointestinal motility in the mouse model of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine( MPTP )-induced PD. Background:…
  • 2023 International Congress

    Pharmacological Invivo and invitro potential of resveratrol in experimental rat models of Parkinson’s disease

    R. Kumar, A. Kanojia (Darbhanga, India)

    Objective: Aim of study was to elucidate the pharmacological Invivo and invitro effects and mechanisms of action ofRT in experimental models of PD. Background: The…
  • 2023 International Congress

    Sub-cellular alterations in MPTP-induced in-vivo and in-vitro systems and Non-MPTP human Parkinsonian skin biopsies: Verifying the sequelae of differential toxicity

    P. Alladi, B. Bhaduri, S. Rashmi, I. Datta, P. Pal, D. Srinivas, R. Yadav (Bangalore, India)

    Objective: To evaluate the possible temporal hierarchy of sub-cellular organellar degeneration in experimental models of Parkinson’s disease (PD), using MPTP/MPP+ Background: Higher prevalence of PD in…
  • 2023 International Congress

    Comparative whole transcriptome analysis of human and mice models of Parkinson’s disease bearing defective glucocerebrosidase activity revealed alteration of expression profile of genes involved in the autophagy

    A. Bezrukova, K. Basharova, M. Rudenok, M. Nikolaev, A. Kopytova, I. Miliukhina, A. Emelyanov, M. Shadrina, P. Slominsky, S. Pchelina, T. Usenko (Gatchina, Russian Federation)

    Objective: To identify potential biomarkers of Parkinson's disease (PD) associated with dysfunction of enzyme glucocerebrosidase (GCase) by a comparative whole transcriptome analysis of animal models…
  • 2022 International Congress

    Protective mechanism of melatonin via heat shock protein in the MPP+-induced in vitro Parkinson’s disease model

    YJ. Jung, E. Oh, A. Kim, H. Choi (Daejeon, Republic of Korea)

    Objective: The objective of this study was to investigate the protective properties of melatonin in an in vitro Parkinson’s disease (PD) model, especially focusing on…
  • 2022 International Congress

    Lack of Toll-like receptor 4 is associated with accumulation of alpha-synuclein in the midbrain Parkinson’s disease mice.

    C. Conte, G. Mariucci, R. Cafaro (Perugia, Italy)

    Objective: In this study we aimed to investigate the potential role of Toll-like receptor 4 (TLR4) in mediating both the dopaminergic neuron loss and alpha-synuclein (alpha-SYN)…
  • 2022 International Congress

    SCFAs participate in the pathogenesis of Parkinson’s disease by regulating NLRP3 inflammasomes activation

    Z. Mao, J. Xiong, Z. Min, Z. Xue (Wuhan, China)

    Objective: To explore the role and related mechanism of gut microbiota metabolites short-chain fatty acids(SCFAs) in the pathogenesis of Parkinson's disease(PD). Background: Growing research have…
  • 2022 International Congress

    Pharmacological activation of Rev-erbα Provides Neuroprotection against Parkinson’s Disease

    L. Kou (Wuhan, China)

    Objective: In this study, we investigated the effects of SR9009, a Rev-ERB agonist, on the dopaminergic system in the MPTP model of PD. Background: Circadian…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 7
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley